Studies

Figure: Total Cancer Patient Treated per Year

Study Overview

Astra-Zeneca D5660C-00004: PD-L1-AK + Stat3-ASO / + CXCR2 Inhibitor in HNSCC, EudraCT No.: 2015-002525-19
Merck EMR 200647-001: PD-L1-AK – TGFbeta ligand trap, metastatic or locally advanced solid tumors and expansion to selected indications, EudraCT 2015-004366-28

(C) ECT.Net 2017. All rights reserved.